News

Research Study: Impact of COVID-19 on People Living with Rare Diseases and Their Families

The novel coronavirus pandemic can have a serious impact on people with rare diseases and their families. Yet, not much is known about it. We want to learn from you and hope that you are willing to share your experience. The Rare Diseases Clinical Research Network’s (RDCRN) Data Management and Coordinating Center, which is supported …

Research Study: Impact of COVID-19 on People Living with Rare Diseases and Their Families Read More »

Patient Focused Drug Development Meeting on Krabbe Disease

NORD invites you to register for an externally-led Patient-Focused Drug Development (EL- PFDD) virtual meeting on Krabbe disease, taking place Thursday, October 29, 12:30 – 4:30 pm ET. Patients and caregivers impacted by Krabbe disease who are interested in potentially speaking at the meeting as panelists should be sure to fill out this form by August 7. If you …

Patient Focused Drug Development Meeting on Krabbe Disease Read More »

Minoryx Nexus Clinical Study for cALD

Minoryx Therapeutics is recruiting for a clinical trial focusing on cALD in Europe. The NEXUS clinical trial is a phase 2, open-label clinical study designed to assess the efficacy and safety of leriglitazone in male pediatric patients with early stage cerebral X-linked adrenoleukodystrophy (cALD). The NEXUS study recruits cALD patients with early cerebral MRI lesions. …

Minoryx Nexus Clinical Study for cALD Read More »

#GivingTuesdayNow is May 5, 2020

Join the Global Day of Giving and Unity! #GivingTuesdayNow is set to take place on May 5, 2020 as an emergency response to the unprecedented need caused by COVID-19. The day is designed to drive an influx of generosity, citizen engagement, business and philanthropy activation, and support for communities and nonprofits around the world. At …

#GivingTuesdayNow is May 5, 2020 Read More »

Life During the Covid-19 Crisis: A Chat with Dr. Bernard

by The Montreal Children’s Hospital Foundation Dr. Geneviève Bernard is a world-renowned expert on genetically determined white matter disorders, called leukodystrophies. Patients are referred to her clinic from all over the world. She brings much comfort to families everywhere who are suffering from these diseases for which the vast majority currently have no known cure. …

Life During the Covid-19 Crisis: A Chat with Dr. Bernard Read More »

A Message about Safety and COVID-19

March 2020  Dear ULF Community,  On behalf of the Board of Directors, Medical and Scientific Advisory Board, and the staff of the ULF, please know that we are following the developments of COVID-19 and feel the concerns of our community. At this time, all we can offer is advice on staying healthy and safe during …

A Message about Safety and COVID-19 Read More »

A Letter from the ULF President

Dear Friends and Supporters of the United Leukodystrophy Foundation,  As the President of the ULF I am excited to talk to you about the many changes that are taking place as we build the future of the Foundation. In the past year, we’ve added seven new members to our board of directors. These new additions …

A Letter from the ULF President Read More »

Embolden Study for MLD

Worldwide, MLD occurs in 1 in 40,000 people, primarily children.  Early symptoms of MLD include trouble walking, impaired speech, and muscle weakness. The Embolden Study is conducting research for infants and children born with metachromatic leukodystrophy. Study overview: The Embolden Study is evaluating the safety and effects of a study drug on gross motor function (the abilities …

Embolden Study for MLD Read More »